iYSyngene International, a leading global contract research, development, and manufacturing organization (CRDMO), is expanding its biologics capabilities with the addition of a GMP bioconjugation suite at its commercial biologics facility, Unit 3, in Bengaluru. With this strategic enhancement, Syngene will now offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs)—from early discovery to GMP manufacturing—placing it among a select group of CDMOs worldwide with full-service ADC expertise.
Accelerating ADC Development Timelines
The new OEB-5 rated suite is designed to streamline ADC development by enabling monoclonal antibody (mAb) production and GMP bioconjugation at a single site. This integration eliminates the need for multiple vendors and reduces supply chain complexity, significantly shortening development timelines. The facility will also complement Syngene’s established commercial-scale capabilities in payload and linker manufacturing, providing clients with a unified and efficient solution for ADC programs.
Expected to become operational within this financial year, the suite will also support a broad spectrum of advanced conjugates and related modalities. Co-located analytical and bioanalytical laboratories will ensure seamless process integration. They will also provide comprehensive characterization throughout the development lifecycle.
Enhancing Global Competitiveness through Integration
Commenting on the development, Alex Del Priore, Head – LM CDMO, Syngene International, said, “The discovery and development of ADCs is complex, often involving multiple vendors and geographically dispersed facilities, which adds supply chain challenges and delays. By integrating bioconjugation with our commercial-scale biologics, payload, and linker production units in Bengaluru, we can substantially compress development timelines and offer a unique end-to-end pathway from discovery to GMP manufacturing.”
Building on a Decade of ADC Expertise
Syngene has over a decade of experience in ADC discovery. The company also has expertise in handling high-potency payloads, linkers, and monoclonal antibodies under GMP-compliant conditions. The company is now scaling its operations to support clinical programs. It has also plans to expand further into commercial-scale ADC manufacturing in the near future.
Comprehensive Services for Biotech and Biopharma Clients
The new laboratories will deliver process development, analytical characterization, and scale-up solutions for both early- and late-stage programs. This addition enhances Syngene’s ability to serve biotech and biopharma partners seeking agile, science-driven support for their ADC pipelines.
Commitment to Innovation and Operational Excellence
Through this expansion, Syngene reinforces its commitment to innovation, quality, and operational excellence. ADC development remains one of the fastest-growing therapeutic segments globally. With more ADC molecules entering clinical trials, Syngene’s integrated model positions it as a trusted partner. It advances next-generation targeted therapies from discovery to delivery.